$ORIC earnings report

ORIC reports Q3 2026 net loss of $(48,076) thousand as R&D expenses rise to $43.4 million. AlphAI read Oric Pharmaceuticals's Q3 FY2026 filing as mixed.

Q3 FY2026

AlphAI · Earnings readORIC · Q3 2026 · ended 2026-09-30

ORIC reports Q3 2026 net loss of $(48,076) thousand as R&D expenses rise to $43.4 million

→Mixed quarter

The filing reports clinical and regulatory progress, including the start of the Himalayas-1 Phase 3 trial and the planned Redwood-1 trial, but the company reports no revenue, the net loss and operating expenses increased year over year, and total assets and equity declined from December 31, 2025.

EPS · GAAP
$(0.44)

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Research and development expenses, three months ended September 30, 2026GAAP$43.4M–increase of $14.6 million
General and administrative expenses, three months ended September 30, 2026GAAP$8.2M–increase of $0.3 million
Total operating expenses, three months ended September 30, 2026GAAP$51.55M––
Loss from operations, three months ended September 30, 2026GAAP−$51.55M––
Other income, net, three months ended September 30, 2026GAAP$3.48M––
Net loss, three months ended September 30, 2026GAAP−$48.08M––
Net loss per share, basic and diluted, three months ended September 30, 2026GAAP$(0.44)––
Comprehensive loss, three months ended September 30, 2026GAAP−$48.75M––
Research and development expenses, nine months ended September 30, 2026GAAP$111.1M–increase of $27.1 million
General and administrative expenses, nine months ended September 30, 2026GAAP$25.4M–increase of $0.9 million
Total operating expenses, nine months ended September 30, 2026GAAP$136.5M––
Loss from operations, nine months ended September 30, 2026GAAP−$136.5M––
Other income, net, nine months ended September 30, 2026GAAP$11.13M––
Net loss, nine months ended September 30, 2026GAAP−$125.3M––
Net loss per share, basic and diluted, nine months ended September 30, 2026GAAP$(1.17)––
Comprehensive loss, nine months ended September 30, 2026GAAP−$127.8M––
Cash, cash equivalents and investments as of September 30, 2026other$345.4M––
Total assets as of September 30, 2026GAAP$366.9M––
Total stockholders' equity as of September 30, 2026GAAP$339.5M––

Capital returns

  • The filing reports $59.9 million in net proceeds raised from healthcare specialist funds during the first quarter under the at-the-market (ATM) program; this amount is included in the $345.4 million of cash, cash equivalents and investments as of September 30, 2026.
  • No share repurchases or dividends are reported in the filing.

What drove it

  • The company attributes the R&D increase for the three months ended September 30, 2026 primarily to higher external expenses related to the advancement of rinzimetostat, partly offset by lower enozertinib costs due to the timing of manufacturing and clinical costs.
  • The company attributes the nine-month R&D increase to higher external expenses related to rinzimetostat, partly offset by lower enozertinib costs due to the timing of manufacturing and clinical costs, and lower preclinical costs.
  • The company attributes the G&A increases for both periods primarily to higher professional services costs.
  • The company initiated the Himalayas-1 global Phase 3 trial in post-abiraterone mCRPC, supported by a clinical trial collaboration and supply agreement with Bayer, under which Bayer provides darolutamide at no cost for the trial.
  • The company announced the Redwood-1 global Phase 3 trial in 1L EGFR atypical NSCLC, with initiation expected in 1H 2027.
  • The company entered an agreement with Cancer Research UK under which CRUK will fully fund, sponsor and execute CTA-enabling activities and early clinical development of ORIC-259; ORIC retains an option to reacquire rights following Phase 1/2 data.

Concerns

  • The filing reports no revenue line; the company's results consist of operating expenses, other income and net loss.
  • Net loss increased to $(48,076) thousand for the three months ended September 30, 2026 from $(32,587) thousand a year earlier, and to $(125,335) thousand for the nine months from $(98,963) thousand.
  • Total operating expenses rose to $51,551 thousand from $36,671 thousand for the quarter.
  • Total assets fell to $366,886 thousand from $408,890 thousand at December 31, 2025, and stockholders' equity fell to $339,503 thousand from $384,362 thousand over the same period.
  • The company's cash, cash equivalents and investments of $345.4 million include $59.9 million from ATM proceeds raised in the first quarter.
  • The safety and efficacy data are described by the company as preliminary, with 28% of patients ongoing in the post-abiraterone cohort and 32% in the post-AR inhibitor cohort.
  • The enozertinib data presented at ESMO Congress 2026 are described as Phase 1b data, and median PFS and duration of response were immature as of the data cutoff.

What to watch

  • The anticipated primary endpoint readout from the first Phase 3 trial for rinzimetostat; the filing does not give a timing for this readout.
  • The 2H 2026 rinzimetostat program update.
  • Initiation of the Redwood-1 Phase 3 trial in 1H 2027.
  • Mid-2027 enozertinib data for the 1L EGFR exon 20 monotherapy and the combinations with SC amivantamab and chemotherapy.
  • Whether R&D expense continues to rise as the Himalayas-1 trial enrolls, which the company plans for approximately 600 patients across over 250 sites in 25 countries.
  • Whether the cash runway into 2H 2028 holds, given the reported decline in cash and investments and the need for additional funding that the company's risk factors describe.

Balance sheet and cash flow

  • Cash, cash equivalents and short-term investments were $261,376 thousand as of September 30, 2026, compared with $281,488 thousand as of December 31, 2025.
  • Long-term investments were $83,986 thousand as of September 30, 2026, compared with $110,762 thousand as of December 31, 2025.
  • Total assets were $366,886 thousand as of September 30, 2026, compared with $408,890 thousand as of December 31, 2025.
  • Total liabilities were $27,383 thousand as of September 30, 2026, compared with $24,528 thousand as of December 31, 2025.
  • Total stockholders' equity was $339,503 thousand as of September 30, 2026, compared with $384,362 thousand as of December 31, 2025.
  • The company expects its cash and investments to fund the operating plan into 2H 2028.
  • The filing does not include a cash flow statement, so operating cash flow and free cash flow are not reported.

Analysis

ORIC reported a net loss of $(48,076) thousand for the three months ended September 30, 2026, against $(32,587) thousand a year earlier, and a net loss of $(125,335) thousand for the nine months against $(98,963) thousand. The filing reports no revenue line, so the results reflect operating expenses and other income only. Total operating expenses for the quarter were $51,551 thousand against $36,671 thousand, with R&D at $43.4 million against $28.8 million and G&A at $8.2 million against $7.9 million. Other income, net was $3,475 thousand against $4,084 thousand for the quarter.

The company's own explanation for the R&D increase is higher external expenses related to the advancement of rinzimetostat, partly offset by lower enozertinib costs tied to the timing of manufacturing and clinical costs. The nine-month R&D figure of $111.1 million against $84.0 million carries the same explanation, with lower preclinical costs also cited. G&A increases are attributed by the company to higher professional services costs. The spending mix therefore points toward the rinzimetostat Phase 3 program, which the company says has begun with Himalayas-1, while enozertinib spending is lower in the period.

On capital, cash, cash equivalents and investments were $345.4 million at September 30, 2026, including $59.9 million of net ATM proceeds raised in the first quarter. The balance sheet shows total assets of $366,886 thousand and stockholders' equity of $339,503 thousand, compared with $408,890 thousand and $384,362 thousand at December 31, 2025. The company expects this cash to fund its operating plan into 2H 2028. The filing contains no cash flow statement, so operating cash burn for the period is not reported.

Clinical updates are the main content of the release. The company reported rinzimetostat safety data from a pre-planned Periodic Safety Review and landmark rPFS estimates in both mCRPC cohorts, which it describes as preliminary. It also presented enozertinib Phase 1b data at ESMO Congress 2026 with an 84% systemic ORR and a 70% CNS ORR by investigator, and announced the Redwood-1 Phase 3 trial with initiation expected in 1H 2027. The filing gives no financial guidance, so no guided figures can be compared with actual results.

The figures that deserve attention are the widening net loss, the rise in operating expenses in both periods, and the decline in total assets and equity since year-end. The clinical programs are described in the release in detail, but the filing does not provide the revenue, gross margin, cash flow or guidance figures that would allow a full financial comparison.

Management, verbatim

Recent clinical data updates reinforce our confidence in the best-in-class potential of our late-stage portfolio, with rinzimetostat continuing to demonstrate an efficacy and safety profile in prostate cancer that is differentiated from current standards of care and the only other PRC2 inhibitor in Phase 3 development, and with enozertinib setting a new benchmark in 1L EGFR atypical NSCLC

Jacob M. Chacko, M.D., president and chief executive officer

With the first Phase 3 trials either underway or planned across both programs and supported by a strong balance sheet, we are laser focused on execution in pursuit of our mission to Overcome Resistance In Cancer

Jacob M. Chacko, M.D., president and chief executive officer

Not in the filing

stated, not guessed
  • No revenue or collaboration revenue line is reported in the filing.
  • No cost of sales or gross margin is reported.
  • No prior-quarter (June 30, 2026) figures are printed for any results line.
  • Percentage changes for total operating expenses, loss from operations, net loss, other income and EPS are not printed.
  • The prior-year figure for cash, cash equivalents and investments at September 30, 2025 is not printed.
  • The December 31, 2025 balance sheet figures are not year-over-year comparatives, so the prior_year fields for total assets and stockholders' equity are null.
  • No cash flow statement is included, so operating cash flow, investing cash flow, financing cash flow and free cash flow are not reported.
  • No debt or borrowing figures are reported.
  • No financial guidance or outlook figures are reported.
  • No non-GAAP measures or reconciliations are reported.
  • No timing is given for the anticipated primary endpoint readout from the first rinzimetostat Phase 3 trial.
  • Revenue by segment or product line is not reported, and the filing does not identify separate reportable segments.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about ORIC earnings dates

When is Oric Pharmaceuticals's next earnings date?
AlphAI has no date for ORIC yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.